If a severe deficiency is found, a loading dose phase may be recommended, consisting of weekly injections for the first month
Evidence snapshot: The strongest available evidence is a small Phase 1 human trial (Teichman et al., 2006) showing dose-dependent, sustained elevation of GH and IGF-1 in healthy adults
FDA has identified BPC-157 among substances considered in the context of bulk drug substances used in compounding, citing concerns that include potential immunogenicity risks, peptide-related impurities, and incomplete active-material characterizationunderscoring the need to avoid consumer-use, clinical-use, or self-administration interpretation
Other than gut healing, it also improves digestion
While no official human dosing guidelines exist, anecdotal use and rodent-to-human conversions help shape general best practices
How to Dose BPC 157 and TB 500: Protocols and Considerations Now we're at the core of the issue